• 1
    Bladé J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158: 18891893.
  • 2
    Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J, for the Nordic Myeloma Study Group. Renal function in newly diagnosed multiple myeloma: a demographic study of 1353 patients. Eur J Haematol. 1994; 53: 207212.
  • 3
    Knudsen LM, Hjorth M, Hippe E, for the Nordic Myeloma Study Group. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol. 2000; 65: 175181.
  • 4
    Sakhuja V, Jha V, Varma S, et al. Renal involvement in multiple myeloma: a 10-year study. Renal Fail. 2000; 22: 465477.
  • 5
    Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102: 11151123.
  • 6
    Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 26092617.
  • 7
    Richardson PG, Barlogie B, Berenson J, et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: an update with additional follow-up. Hematol J. 2004; 5(Suppl 2): S103.
  • 8
    Jagannath S, Barlogie B, Berenson J, et al. A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004; 127: 165172.
  • 9
    Richardson P, Sonneveld P, Schuster MW, et al. Bortezomib vs. dexamethasone in relapsed multiple myeloma: a Phase 3 randomized study. Proc Am Soc Clin Oncol. 2004; 23: 558.
  • 10
    Millennium Pharmaceuticals, Inc. Data on file. Cambridge: Millennium Pharmaceuticals, Inc., 2004.
  • 11
    Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000; 46: 673683.
  • 12
    Jagannath S, Richardson P, Barlogie B. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc Am Soc Clin Oncol. 2003; 22: 582.
  • 13
    Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003; 122: 441450.
  • 14
    Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 2133.
  • 15
    Desikan KR, Tricot G, Munshi NC, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001; 112: 242247.
  • 16
    Mallick NP, Olujohungbe A, Drayson MT. Renal impairment in myeloma: time for a reappraisal? Nephrol Dial Transplant. 1998; 13(Suppl 7): 3032.
  • 17
    Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001; 114: 822829.
  • 18
    San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000; 1: 2836.
  • 19
    National Cancer Institute. Bortezomib in treating patients with advanced cancer and kidney dysfunction. Available at: [accessed April 14, 2004].